<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30151375</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">2314-6141</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>2018</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>BioMed research international</Title>                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>            </Journal>            <ArticleTitle>Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients.</ArticleTitle>            <Pagination>                <MedlinePgn>2124390</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2018/2124390</ELocationID>            <Abstract>                <AbstractText>The aim of this study was to investigate plasma levels and applicability of CCL2, CCR2, and tumor marker CA 15-3 in breast cancer (BC) patients and in relation to the control groups: patients with benign breast tumor and healthy subjects. Plasma levels of tested parameters were determined by enzyme-linked immunosorbent assay (ELISA) and CA 15-3 by Chemiluminescent Microparticle Immunoassay (CMIA). The median levels of CCL2 in entire group of BC were significantly higher compared to the control groups, similarly as median levels of CA 15-3. CCR2 is a negative marker whose levels were significantly lower in BC group compared to healthy women. The concentration of CCL2 in BC increases with advancing tumor stage, while a median level of CCR2 decreases with advancing stage. CCL2 showed the highest value of sensitivity (SE) (64.95%) in entire BC group and also in early stages of disease. The highest specificity (SP) was obtained by CA 15-3 (85.71%). The area under the ROC curve (AUC) of CCR2 (0.7304) was the largest of all the tested parameters (slightly lower than CA 15-3) in the entire BC group, but a maximum range was obtained for the combination of all tested parameters with CA 15-3 (0.8271). In early stages of BC the highest AUC of all tested parameters was observed in CCL2 or CCR2 (stage I: 0.6604 and 0.6564; respectively; stage II: 0.7768, respectively, for CCR2). The findings of this study suggest that there may be applicability of CCL2, CCR2 in diagnosis of BC patients, particularly in conjunction with CA 15-3.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lubowicka</LastName>                    <ForeName>Emilia</ForeName>                    <Initials>E</Initials>                    <Identifier Source="ORCID">0000-0001-5002-4076</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Esthetic Medicine, Medical University of Bialystok, 15-267 Bialystok, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Przylipiak</LastName>                    <ForeName>Andrzej</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Esthetic Medicine, Medical University of Bialystok, 15-267 Bialystok, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zajkowska</LastName>                    <ForeName>Monika</ForeName>                    <Initials>M</Initials>                    <Identifier Source="ORCID">0000-0002-5179-0722</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Piskór</LastName>                    <ForeName>Barbara Maria</ForeName>                    <Initials>BM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Esthetic Medicine, Medical University of Bialystok, 15-267 Bialystok, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Malinowski</LastName>                    <ForeName>Paweł</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Surgery, Bialystok Oncology Center, Bialystok, 15-276 Bialystok, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fiedorowicz</LastName>                    <ForeName>Wojciech</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncological Surgery, Bialystok Oncology Center, Bialystok, 15-276 Bialystok, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ławicki</LastName>                    <ForeName>Sławomir</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>30</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Biomed Res Int</MedlineTA>            <NlmUniqueID>101600173</NlmUniqueID>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2007 Sep 1;13(17):5020-7</RefSource>                <PMID Version="1">17785552</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pathol. 2012 Jan;226(2):148-57</RefSource>                <PMID Version="1">21989643</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2004 Jan-Apr;25(1-2):14-7</RefSource>                <PMID Version="1">15192307</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2010 Aug 15;127(4):759-67</RefSource>                <PMID Version="1">20518016</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Immunol. 2007;25:787-820</RefSource>                <PMID Version="1">17291188</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Dis Markers. 2016;2016:7963895</RefSource>                <PMID Version="1">27041792</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thorac Oncol. 2012 May;7(5):883-9</RefSource>                <PMID Version="1">22729037</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomarkers. 2017 Mar;22(2):157-164</RefSource>                <PMID Version="1">27775427</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1999 Sep 15;59(18):4681-7</RefSource>                <PMID Version="1">10493525</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neoplasia. 2006 Jul;8(7):578-86</RefSource>                <PMID Version="1">16867220</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>In Vivo. 2010 Mar-Apr;24(2):243-8</RefSource>                <PMID Version="1">20364004</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2011 Jun 08;475(7355):222-5</RefSource>                <PMID Version="1">21654748</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Asian Pac J Cancer Prev. 2016;17(S3):43-6</RefSource>                <PMID Version="1">27165206</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Rep. 2015 Jul 14;12(2):244-57</RefSource>                <PMID Version="1">26146082</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Cell Res. 2011 Mar 10;317(5):685-90</RefSource>                <PMID Version="1">21040721</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2002 Dec 19-26;420(6917):860-7</RefSource>                <PMID Version="1">12490959</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2013 Oct 1;73(19):6080-93</RefSource>                <PMID Version="1">23959857</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2011 Jan 15;71(2):603-13</RefSource>                <PMID Version="1">21123450</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2001 Sep 1;92(5):1085-91</RefSource>                <PMID Version="1">11571719</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Lett. 2008 Aug 28;267(2):271-85</RefSource>                <PMID Version="1">18439751</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Mol Med. 2010 Mar;16(3):133-44</RefSource>                <PMID Version="1">20163989</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cytokine. 2008 Oct;44(1):191-200</RefSource>                <PMID Version="1">18790652</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2012 Jan;131(2):401-11</RefSource>                <PMID Version="1">21344235</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Res Clin Oncol. 2005 Jul;131(7):453-8</RefSource>                <PMID Version="1">15883814</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2015 Mar;65(2):87-108</RefSource>                <PMID Version="1">25651787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2014 Jun 19;33(25):3217-24</RefSource>                <PMID Version="1">23851506</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Metastasis Rev. 2007 Dec;26(3-4):401-20</RefSource>                <PMID Version="1">17717637</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pathol Res Pract. 1998;194(5):335-40</RefSource>                <PMID Version="1">9651946</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2007 Mar;17(3):687-94</RefSource>                <PMID Version="1">17273752</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ir J Med Sci. 2018 Aug;187(3):767-775</RefSource>                <PMID Version="1">29086194</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2013 Jan 15;73(2):662-71</RefSource>                <PMID Version="1">23329645</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Lab. 2016 Sep 1;62(9):1661-1669</RefSource>                <PMID Version="1">28164586</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2001 Feb 17;357(9255):539-45</RefSource>                <PMID Version="1">11229684</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Onco Targets Ther. 2016 Feb 24;9:911-9</RefSource>                <PMID Version="1">26966379</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pol Arch Med Wewn. 2015;125(6):443-51</RefSource>                <PMID Version="1">26020569</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Immunol Lett. 2005 Jan 15;96(1):55-61</RefSource>                <PMID Version="1">15585308</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2006 Jan 1;118(1):35-42</RefSource>                <PMID Version="1">16003740</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Anaesthesiol. 2016 May;33(5):348-55</RefSource>                <PMID Version="1">26771764</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Immunol. 2000;18:217-42</RefSource>                <PMID Version="1">10837058</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mediators Inflamm. 2016;2016:5962946</RefSource>                <PMID Version="1">27445439</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Immunity. 2012 May 25;36(5):705-16</RefSource>                <PMID Version="1">22633458</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Interferon Cytokine Res. 2009 Jun;29(6):313-26</RefSource>                <PMID Version="1">19441883</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2012 Mar 20;21(3):309-22</RefSource>                <PMID Version="1">22439926</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30151375</ArticleId>            <ArticleId IdType="doi">10.1155/2018/2124390</ArticleId>            <ArticleId IdType="pmc">PMC6091289</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>